Using Pressurized Aerosol Chemotherapy for Peritoneal Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in treating patients with peritoneal metastases from unresectable colorectal, gastric, and pancreatic cancers. The study involves administering PIPAC with oxaliplatin, doxorubicin, and cisplatin, aiming to assess its therapeutic efficacy and safety in a single-arm, open-label format. Participants will receive three cycles of PIPAC along with systemic chemotherapy, with treatments repeated every 6-8 weeks. The trial focuses on patients who have not previously undergone PIPAC and are treatment-naïve or have progressed on first-line systemic therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. ≥18 years of old;
2. WHO performance of status 0-1;
3. Histologically or cytologically proven PM of a gastric, pancreatic or colorectal carcinoma;
4. Treatment naïve patients as first-line treatment;
5. Progression on or intolerance to first-line systemic chemotherapy as second-line treatment;
6. No symptoms of gastrointestinal obstruction;
7. No contraindications for the planned systemic therapy or laparoscopy;
8. No previous PIPAC/IP/HIPEC;
9. No other concurrent malignancies or any other malignancy within 6 months prior to enrolment;
10. Able to give written informed consent.

Exclusion Criteria:

1. A history of allergic reaction to platinum containing compounds or doxorubicin;
2. Pregnant or breastfeeding;
3. Any extra-peritoneal metastases;
4. Renal impairment, defined as GFR less than 40 mL/min;
5. Impaired liver function defined as bilirubin over 1.5 × UNL;
6. Inadequate haematological function

   * Leucocyte \< 3.00 × 109/L
   * Absolute neutrophil counts \< 1.50 × 109/L
   * Platelet \< 100 × 109/L

Where it's running

• Queen Mary Hospital
  Hong Kong, Hong Kong Recruiting

Study contacts

• Principal investigator: Ian WONG, Dr. — The University of Hong Kong
• Study coordinator: Ian WONG, Dr.
• Email: iyhwong@hku.hk
• Phone: +852 2255 4774

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TROP2‑targeted CAR‑NK cells given into the abdomen and vein for colorectal cancer spread to the peritoneum

  We will test whether giving TROP2‑directed CAR‑NK cells both into the abdominal cavity and into a vein, together with cetuximab, is safe and what dose is best for adults with colorectal cancer that has spread to the peritoneum.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT07411599

• Mass-based drug screening to guide personalized HIPEC for high-grade appendiceal and colorectal cancer with peritoneal spread.

  This tests whether a lab-based mass response test on tumor biopsies can pick the best chemotherapy to use during repeated HIPEC for people with unresectable peritoneal metastases from high-grade appendiceal or colorectal cancer.

  Recruiting Yale University · New Haven, Connecticut · NCT07291180

• Direct injection of a modified vaccinia virus (vvDD-hIL2) into abdominal and gastrointestinal tumors

  This trial will try a single direct injection of a modified vaccinia virus (vvDD-hIL2) into abdominal tumors to see if it is safe for adults with advanced metastatic gastrointestinal or peritoneal cancers who have not responded to standard treatments.

  Recruiting Phase 1 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT07001592

• Monitoring blood markers to predict colorectal cancer recurrence after surgery

  This study is testing if blood markers can help predict if colorectal cancer will come back after surgery in patients who have had their cancer completely removed.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT06903325

• Treatment for advanced gastric cancer with peritoneal metastasis using a combination of therapies

  This study is testing a new combination of treatments for people with advanced gastric cancer that has spread to the abdomen to see if it can help slow down the disease and improve their health.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Huangpu District · NCT06519591

• Understanding biomarkers in metastatic colorectal cancer treatment

  This study is trying to see how cancer changes during treatment in people with metastatic colorectal cancer and whether certain genetic markers can help tailor better treatment options for them.

  Recruiting at 2 sites Region Skane · Lund, Skåne County and 1 other locations · NCT05755672

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.